CSL Limited - Product Pipeline Review - 2015

1
CSL Limited - Product Pipeline Review - 2015
Published on October - 2015
2
.
Report Overview
About CSL Limited - Product Pipeline Review -
2015 Research Beam added report on CSL Limited
Product Pipeline Review - 2015. CSL Limited
Product Pipeline Review 2015 Summary Global
Markets Directs, CSL Limited Product Pipeline
Review - 2015, provides an overview of the CSL
Limited s CSL Limited research and development
focus. This report provides comprehensive
information on the current therapeutic
developmental pipeline of CSL Limited s, complete
with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type. It also reviews latest
updates, and featured news and press releases,
along with special features on late-stage and
discontinued projects. Get Full Details On
http//www.researchbeam.com/csl-limited-product-pi
peline-review-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.
4
.
Report Overview
Scope The report provides brief overview of CSL
Limited including business description, key
information and facts, and its locations and
subsidiaries The report reviews current pipeline
of CSL Limited s human therapeutic division and
enlists all their major and minor projects The
report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
CSL Limited s pipeline products  
5
Report Overview

• Reasons to buy
•  Evaluate CSL Limited s strategic position with
  total access to detailed information on its
  product pipeline
• Assess the growth potential of CSL Limited in its
  therapy areas of focus
• Identify new drug targets and therapeutic classes
  in the CSL Limited s RD portfolio and develop
  key strategic initiatives to reinforce pipeline
  in those areas
• Exploit in-licensing opportunities by identifying
  windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding
  the focus areas of CSL Limited and exploit
  collaboration and partnership opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of CSL
  Limited
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  CSL Limited and identify potential opportunities
  in those areas

6
Table Of Contents
Table of Contents 2List of Tables 6List of
Figures 6CSL Limited Snapshot 7CSL Limited
Overview 7Key Information 7Key Facts 7CSL
Limited - Research and Development Overview 8Key
Therapeutic Areas 8CSL Limited - Pipeline Review
11Pipeline Products by Stage of Development
11Pipeline Products - Monotherapy 12Pipeline
Products - Combination Treatment Modalities
13Pipeline Products - Partnered Products 14
7
Table Of Contents
Partnered Products/Combination Treatment
Modalities 15Pipeline Products - Out-Licensed
Products 16Out-Licensed Products/Combination
Treatment Modalities 17CSL Limited - Pipeline
Products Glance 18CSL Limited - Late Stage
Pipeline Products 18 Partnered Products/Combinatio
n Treatment Modalities 15Pipeline Products -
Out-Licensed Products 16Out-Licensed
Products/Combination Treatment Modalities 17CSL
Limited - Pipeline Products Glance 18CSL Limited
- Late Stage Pipeline Products 18
8
Table Of Contents
Pre-Registration Products/Combination Treatment
Modalities 18Filing rejected/Withdrawn
Products/Combination Treatment Modalities
19Phase III Products/Combination Treatment
Modalities 20CSL Limited - Clinical Stage
Pipeline Products 21Phase II Products/Combination
Treatment Modalities 21Phase I
Products/Combination Treatment Modalities 22CSL
Limited - Early Stage Pipeline Products
23Preclinical Products/Combination Treatment
Modalities 23Discovery Products/Combination
Treatment Modalities 24 Enquiry about this
report _at_ http//www.researchbeam.com/csl-limited-p
roduct-pipeline-review-2015-market/enquire-about-r
eport
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/csl-limited-product-pi
peline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com